2022 World Conference on Lung Cancer (Posters)-P1.15-03. Clinical Outcomes Among Patients With Non-small Cell Lung Cancer Who Discontinued Immune Checkpoint Inhibitors Due to Toxicity

P1.15-03. Clinical Outcomes Among Patients With Non-small Cell Lung Cancer Who Discontinued Immune Checkpoint Inhibitors Due to Toxicity

Pdf Summary

This study aimed to evaluate the clinicopathologic characteristics and outcomes of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitors (ICIs) due to immune-related adverse events (irAEs). The researchers analyzed data from 1038 NSCLC patients treated with ICIs, of whom 114 (11%) discontinued treatment due to irAEs. The median duration of ICI treatment before discontinuation for irAEs was 4.8 months. Gastrointestinal and pulmonary irAEs were the most common reasons for ICI discontinuation in patients with early and late permanent discontinuation, respectively. The use of corticosteroids for managing irAEs did not impact post-discontinuation progression-free survival (PFS) and overall survival (OS). Notably, patients with high programmed death ligand 1 (PD-L1) expression may experience prolonged PFS and OS following ICIs discontinuation for irAEs. <br /><br />The study also examined the variables related to post-discontinuation PFS and OS. Sex, age, treatment line, Eastern Cooperative Oncology Group performance status (ECOG-PS), use of steroids for managing irAEs, duration of steroid treatment, tumor mutation burden, and PD-L1-TMB score did not significantly impact post-discontinuation PFS and OS. However, patients with PD-L1 expression of 50% or higher had a significantly improved PFS and OS compared to those with PD-L1 expression below 50%. <br /><br />In conclusion, this study provides insights into the clinicopathologic characteristics and outcomes of NSCLC patients who discontinued ICIs due to irAEs. Gastrointestinal and pulmonary irAEs were the leading causes of ICI discontinuation, and corticosteroid use did not affect post-discontinuation PFS and OS. High PD-L1 expression may serve as a potential biomarker for prolonged PFS and OS following ICIs discontinuation for irAEs. Further research is needed to validate and expand on these findings.

Asset Subtitle

Federica Pecci, United States

Meta Tag

Speaker Federica Pecci, United States

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

non-small cell lung cancer

immune checkpoint inhibitors

immune-related adverse events

clinicopathologic characteristics

patient outcomes

discontinued treatment

irAEs

corticosteroid use

PD-L1 expression

post-discontinuation progression-free survival